Innovative Medicines Initiative (IMI) logo

Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors - IMI2-2018-16-01
Deadline: Oct 24, 2018  
CALL EXPIRED

 Entrepreneurship and SMEs
 Innovation
 Health Care
 Horizon Europe
 Research

Specific Challenge:

The Portfolio Building Network (PBN), Pillar C of the IMI2 JU AMR Accelerator programme, will address the limited pipeline of treatments and preventions for AMR infections by enabling vibrant and nimble collaborations between EFPIA companies and small and medium-sized enterprises (SMEs) and/or academics that will advance the R&D pipeline of new and innovative agents to address AMR.

Scope:

The scope of this action will be to identify and progress novel lead compounds (one preNME and one FTIH start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors towards design and implementation of phase 1 clinical studies.

Expected Impact:

The expected impact of actions selected under this Call will be to: (1) contribute to the development of a vibrant AMR research environment in the EU and strengthen the competitiveness and industrial leadership of Europe; (2) contribute to the EU’s ambition of being a ‘best practice region’ for addressing AMR; (3) enhance the overall pipeline of medicines for patients with AMR infections and advance new and innovative agents.



Public link:   Only for registered users


Looking for a partnership?
Have a look at
Ma Région Sud!
https://maregionsud.up2europe.eu